Your Team for Swiss Law – désormais à Genève

Close

Que voudriez-vous rechercher?

Recherche du site
Filtres de recherche

The Outlook for Chinese Healthcare

On September 25, 2019, VISCHER Manager of China Life Sciences Group Fiona Gao will give a presentation at the 19th Annual Biotech in Europe Forum. Her topic will be The Outlook for Chinese Healthcare: Changing Regulatory & Policy...

How to Structure Your Team

On September 19, 2019, VISCHER partner Dr. Matthias Staehelin will kick off the legal sessions of the BaseLaunch Healthcare Accelerator Program with his presentation on "How to Structure Your Team from a Legal Perspective"....

Besprechung der Dissertation von Leila Ghassemi Farreras

Kohler, Stefan, Besprechung der Dissertation von Leila Ghassemi Farreras "Utilisation of Traditional Medicinal Knowledge in the Industry – Legal Aspects and Protection in International Law", in: sic!, Schulthess Juristische Medien...

Lizenzgebühren im Pharmabereich: Arten, Strukturierung, Besonderheiten

Lizenzgebühren im Pharmabereich: Arten, Strukturierung, Besonderheiten Highlights aus dem Inhalt Arzneimittelentwicklung und Pharma License Deals Kategorien von Vergütungen im Pharma-Lizenzvertrag Upfront Payments Milestone...

Pricing & Reimbursement, Swiss perspective

Highlights aus dem Inhalt Pharmaceutical market in Switzerland Pharmaceutical market by reimbursability Generics Sales outlets by turnover and inventory Biotech and gene tech products Approval of medicines Medicines in the...

TQV-Vergleichsgruppenbildung: «Carte Blanche» für das BAG

Kohler, Stefan, Kommentar zu Urteil 9C_695/2016 vom 30. Oktober 2017, in: dRSK, publiziert am 11. Januar 2018

R&D Collaboration in Switzerland

Kohler, Stefan / Züst, Lukas, R&D Collaboration in Switzerland, in: CBLJ, July/August 2017, pages 34-35.

Das Lizenzobjekt – Ein Überblick

Veranstalter: LES (Licensing Executives Society Switzerland)Ort: Hotel Flora Alpina, Vitznau

Is clampdown on Swiss stem cell therapies justified?

Kesselring Felix/Kohler Stefan, Is clampdown on Swiss stem cell therapies justified?, in: China Business Law Journal Volume 7 Issue 4, April 2016, S. 78 f.

You are currently offline. Some pages or content may fail to load.